Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Spesolimab Coverage Update | OpenPaye…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy RX501.181

    Spesolimab-sbzo for generalized pustular psoriasis

    Customize your policy alerts

    Sign up for healthspring Policy RX501.181 alerts

    Get alerted when Policy RX501.181 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity coverage for spesolimab-sbzo (Spevigo) to treat generalized pustular psoriasis in eligible adults and pediatric patients; self-administered formulations are reviewed under the applicable pharmacy benefit plan.

    Policy Summary
    PayerHealthSpring
    PolicySpesolimab-sbzo for generalized pustular psoriasis
    Policy CodePolicy RX501.181
    Change TypeModified
    Effective DateSep 15, 2026
    Next Review DateN/A
    Key ActionDocument a moderate-to-severe generalized pustular psoriasis flare using at least one accepted clinical measure before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    The existing-flare criterion was revised to require moderate-to-severe generalized pustular psoriasis documented by at least one specified clinical measure.

    A consensus statement from the National Psoriasis Foundation was added as a reference.

    12+Minimum patient age
    40 kgMinimum patient weight
    GPPPGA ≥3Qualifying severity score
    ≥5% BSAAlternative disease threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    All other usesNon-covered uses

    Medical Necessity and Non-Covered Uses

    Medically necessary treatment of generalized pustular psoriasis

    Covered when all of the following are met:

    Patient eligibility and qualifying disease severity

    • Age and weight: The patient is 12 years of age or older and weighs at least 40 kg.Age ≥12 years and weight ≥40 kg
    • Qualifying moderate-to-severe flare

      • Qualifying severity finding: Generalized Pustular Psoriasis Physician Global Assessment score of at least 3.GPPPGA ≥3
      • Qualifying severity finding: GPPPGA pustulation sub-score of at least 2, indicating moderate to very high density pustules.GPPPGA pustulation sub-score ≥2
      • Qualifying severity finding: Fresh pustules are present, defined as new appearance or worsening of pustules.Fresh pustules
      • Qualifying severity finding: At least 5% of body surface area is covered with erythema and the presence of pustules.≥5% BSA with erythema and pustules

    Experimental or unproven indications

    Not covered under this policy:

    Non-FDA-approved indication: Use for any indication other than an FDA-approved indication is considered experimental, investigational, and/or unproven.Non-FDA indication

    Generalized pustular psoriasis treatment

    Covered when all of the following are met:

    Covered treatment criteria

    • Age and weight: The patient is at least 12 years old and weighs at least 40 kg.Age ≥12 years; weight ≥40 kg
    • Existing moderate-to-severe flare

      • Accepted clinical measure: Generalized Pustular Psoriasis Physician Global Assessment score is at least 3.GPPPGA ≥3
      • Accepted clinical measure: GPPPGA pustulation subscore is at least 2, indicating moderate to very high density pustules.

    Spesolimab-sbzo is considered experimental, investigational, and/or unproven for all non-Food and Drug Administration-approved indications.

    Spesolimab-sbzo is considered experimental, investigational, and/or unproven for all other uses outside the policy-supported treatment of generalized pustular psoriasis.

    Code and Clinical Threshold Reference

    HCPCS CodesHCPCS
    J1747
    Patient age12 years of age and older
    Patient weightAt least 40 kg
    GPPPGA total scoreAt least 3
    GPPPGA pustulation sub-scoreAt least 2
    Body surface area with erythema and pustulesAt least 5%

    Documentation and Coverage Actions

    Documentation Required

    Document Eligibility and Disease Severity

    Before coverage can be considered, document that the patient meets the required age, weight, and disease-severity criteria for spesolimab-sbzo (Spevigo®) treatment of generalized pustular psoriasis (GPP).

    • Age and weight: Adult or pediatric patient age 12 years or older and weighing at least 40 kg.
    • Moderate-to-severe GPP: The existing flare is, or was previously noted to be, moderate to severe, documented by at least one of the following: Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) score ≥ 3; GPPPGA pustulation sub-score ≥ 2; fresh pustules (new appearance or worsening); or ≥ 5% body surface area covered with erythema and pustules.
    Prior Authorization

    Complete Required Vaccinations

    Complete all age-appropriate vaccinations according to current immunization guidelines before initiating spesolimab-sbzo (Spevigo®) for GPP.

    Condition Overview

    Generalized pustular psoriasis is a rare, severe form of pustular psoriasis characterized by recurrent flares with widespread erythema and non-follicular pustules. Flares may include systemic inflammation and fever, as well as hepatic, gastrointestinal, musculoskeletal, renal, or pulmonary involvement. Spesolimab-sbzo is a humanized monoclonal antibody that inhibits interleukin-36 signaling by binding to the IL-36 receptor.

    Clinical Definitions

    GPPPGAThe Generalized Pustular Psoriasis Physician Global Assessment is a 5-point scale from 0 to 4 used to assess pustules, scaling, and erythema; higher scores indicate greater disease severity. The total score is based on the average of the three component subscores.
    GPPPGA pustulation sub-scoreThis component assesses pustule density and severity: 2 indicates moderate-density, grouped, discrete, small noncoalescent pustules; 3 indicates high-density pustules with some coalescence; and 4 indicates very high-density pustules with pustular lakes.
    GPPPGA total scoreThe physician assessment of generalized pustular psoriasis severity ranges from 0 (clear) to 4 (severe). The score is calculated from the average of the pustule, erythema, and scaling subscores.
    GPPPGA pustulation subscoreThis component assesses pustule severity; a score of 0 indicates no visible pustules.

    Initial Treatment Requirements

    Initial therapy for generalized pustular psoriasis

    Initial treatment may be considered medically necessary when all eligibility requirements and at least one disease-severity criterion are met:

    Initial therapy eligibility

    • Age and weight: The patient is 12 years of age or older and weighs at least 40 kg.Age ≥12 years and weight ≥40 kg
    • Disease severity

      • Qualifying severity criterion: GPPPGA score is at least 3.GPPPGA ≥3

    Administration Setting

    Billing Rule

    Administer the studied intravenous dose in an infusion center

    The studied treatment was administered in an infusion center as a single intravenous dose of 900 mg over 90 minutes.

    Policy Summary
    PayerHealthSpring
    PolicySpesolimab-sbzo for generalized pustular psoriasis
    Policy CodePolicy RX501.181
    Change TypeModified
    Effective DateSep 15, 2026
    Next Review DateN/A
    Key ActionDocument a moderate-to-severe generalized pustular psoriasis flare using at least one accepted clinical measure before requesting coverage.
    SourceLink
    On This Page
    Medical Necessity and Non-Covered UsesCode and Clinical Threshold ReferenceDocumentation and Coverage ActionsCondition OverviewClinical DefinitionsInitial Treatment RequirementsAdministration Setting
    GPPPGA pustulation subscore ≥2
  1. Accepted clinical measure: Fresh pustules are present, defined as new appearance or worsening of pustules.Fresh pustules
  2. Accepted clinical measure: At least 5% of body surface area is covered with erythema and pustules.≥5% BSA with erythema and pustules
  3. GPPPGA total score>= 3
    GPPPGA pustulation subscore>= 2
    Body surface area with erythema and pustules>= 5%
    Week 1 temperature>38° Celsius
    White blood cell count>12 x 10^9/L
    Patient ageAt least 12 years
    Patient weightAt least 40 kg
    GPPPGA scoreAt least 3
    GPPPGA pustulation subscoreAt least 2
    Body surface areaAt least 5% with erythema and pustules
  4. Verify and document completion of age-appropriate vaccinations before treatment initiation.
  5. Documentation Required

    Required Clinical Documentation

    For an existing or previously noted flare, submit clinical documentation establishing moderate-to-severe GPP using the revised criteria.

    • Document at least one qualifying finding: GPPPGA score ≥ 3; GPPPGA pustulation sub-score ≥ 2 (moderate to very high density pustules); fresh pustules, meaning new appearance or worsening; or at least 5% BSA with erythema and pustules.
    • The documentation must support that the existing flare is, or was previously noted to be, of moderate-to-severe intensity.
    Denial Risk

    Coverage Requirements Must Be Met

    Coverage may be denied when the patient or indication does not satisfy all applicable coverage requirements for treatment of GPP.

    • Patient is younger than 12 years or weighs less than 40 kg.
    • The record does not document moderate-to-severe GPP or at least one qualifying severity finding.
    • The requested use is not for treatment of generalized pustular psoriasis.
    • Self-administered formulations are subject to the applicable pharmacy benefit plan.
    Denial Risk

    Non-Covered or Unproven Use

    Spesolimab-sbzo (Spevigo®) is considered experimental, investigational, and/or unproven for all other non-Food and Drug Administration (FDA) indications. Uses outside supported treatment of GPP may be denied as non-covered or unproven.

    • Do not submit for indications other than FDA-supported treatment of generalized pustular psoriasis unless a separate benefit or policy provision applies.
    Generalized pustular psoriasis flareA moderate-to-severe acute episode characterized in the study by a GPPPGA total score of at least 3, fresh pustules, a GPPPGA pustulation subscore of at least 2, and at least 5% of body surface area covered with erythema and pustules.
    Moderate-to-severe existing flareAn existing or previously noted moderate-to-severe generalized pustular psoriasis flare documented by at least one accepted measure: GPPPGA score of at least 3; GPPPGA pustulation subscore of at least 2; fresh pustules; or at least 5% of body surface area covered with erythema and pustules.
    Qualifying severity criterion:
    GPPPGA pustulation sub-score is at least 2, indicating moderate to very high density pustules.
    GPPPGA pustulation sub-score ≥2
  6. Qualifying severity criterion: Fresh or worsening pustules are present.Fresh pustules
  7. Qualifying severity criterion: At least 5% of body surface area is covered with erythema and pustules.≥5% BSA with erythema and pustules
  8. Initial therapy

    Spesolimab-sbzo may be considered medically necessary for treatment of generalized pustular psoriasis when all criteria are met:

    Initial therapy eligibility

    • Age and weight: The patient is at least 12 years old and weighs at least 40 kg.Age ≥12 years; weight ≥40 kg
    • Existing moderate-to-severe flare

      • Accepted clinical measure: GPPPGA score is at least 3.GPPPGA ≥3
      • Accepted clinical measure: GPPPGA pustulation subscore is at least 2.GPPPGA pustulation subscore ≥2
      • Accepted clinical measure: Fresh pustules are present, defined as new appearance or worsening of pustules.Fresh pustules
      • Accepted clinical measure: At least 5% of body surface area is covered with erythema and pustules.≥5% BSA with erythema and pustules